6. SGRQ class effects versus placebo (six months)^a.

	Effect vs placebo Class NWMA		Effect vs placebo Sensitivity analysis		Rank
Class	Median	95% CrI	Median	95% CrI	Mean	Median	95% CrI	Pr (best)
LABA/ICS	‐3.89	(‐4.70 to ‐2.97)	‐3.89	(‐4.66 to ‐3.05)	1.0	1	(1 to 2)	0.96
LAMA	‐2.63	(‐3.53 to ‐1.97)	‐2.78	(‐3.58 to ‐2.13)	2.4	2	(1 to 4)	0.03
LABA	‐2.29	(‐3.18 to ‐1.53)	‐2.09	(‐2.93 to ‐1.36)	3.1	3	(2 to 4)	0.01
ICS	‐2.00	(‐3.06 to ‐0.87)	‐1.96	(‐2.99 to ‐0.91)	3.5	4	(2 to 4)	0.00

^aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.

Crl = credible interval.

SGRQ = St George's Respiratory Questionnaire.

ICS = inhaled corticosteroid.

LABA = long‐acting beta₂‐agonist.

LABA/ICS = long‐acting beta₂‐agonist/inhaled corticosteroid.

LAMA = long‐acting antimuscarinic antagonist.

NWMA = network meta‐analysis.

Pr = probability.